Home > Insider Trading > Filing (0001209191-14-074765)

Filing Details

Accession Number:: 0001209191-14-074765
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-12-11 21:47:09
Reporting Period:: 2014-12-09

Filing Date:: 2014-12-11
Accepted Time:: 2014-12-11 21:47:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
861838	Idera Pharmaceuticals Inc.	IDRA	Biological Products, (No Disgnostic Substances) (2836)	043072298

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1193366	El Youssef Zein	Pillar Invest Offshore Sal, Starco Ctr, Bloc B, 3Rd Floor, Omar Daouk Street Beirut M8 2020-3313	Yes	No	Yes	No
1534425	Pillar Pharmaceuticals I Lp	Pillar Invest Offshore Sal, Starco Ctr, Bloc B, 3Rd Floor, Omar Daouk Street Beirut M8 2020-3313	Yes	No	Yes	No
1534428	Pillar Invest Corp	C/O Idera Pharmaceuticals, Inc. 167 Sidney Street Cambridge MA 02139	Yes	No	Yes	No
1562069	Pillar Pharmaceuticals Ii, L.p.	Pillar Invest Offshore Sal, Starco Ctr Bloc B, 3Rd Floor, Omar Daouk Street Beirut M8 2020-3313	Yes	No	Yes	No
1576891	Pillar Pharmaceuticals Iii, L.p.	Pillar Invest Offshore Sal Starco Ctr Bloc B, 3Rd Floor Omar Daouk Street Beirut M8 2020-3313	Yes	No	Yes	No
1588130	Pillar Pharmaceuticals Iv, L.p.	Pillar Invest Offshore Sal Starco Ctr Bloc B, 3Rd Floor, Omar Daouk Street Beirut M8 2020-3313	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-12-09	500,000	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-09	569,231	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-09	156,538	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-09	113,846	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-09	85,385	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-10	216,028	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-10	59,408	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-10	43,206	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-10	32,404	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-11	438,836	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-11	120,680	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-11	87,767	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-12-11	65,825	$0.00	No	4	S	Indirect	See Footnotes
Common Stock	Acquisiton	2014-12-09	500,000	$0.00	No	4	X	Indirect	See Footnotes
Common Stock	Acquisiton	2014-12-11	6,266,820	$0.00	No	4	C	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	X	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants	Disposition	2014-12-09	500,000	$0.00	500,000	$0.47
Common Stock	Series E Convertible Preferred Stock	Disposition	2014-12-11	313,341	$0.00	6,266,820	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-05-07	2018-05-07	No	4	X	Indirect
0			No	4	C	Indirect

Footnotes

Shares sold by Participations Besancon ("Besancon"), a fund advised by Pillar Invest Corporation ("Pillar GP"). Pillar GP disclaims Section 16 beneficial ownership of the Besancon Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, resulting from fees payable to Pillar GP in its capacity as investment advisor to Besancon. As of the date hereof, Besancon owns directly 3,439,933 shares of common stock of the Issuer.
Shares sold by Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar I. As of the date hereof, Pillar I owns directly 3,647,838 shares of common stock of the Issuer.
Shares sold by Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. As of the date hereof, Pillar II owns directly 701,715 shares of common stock of the Issuer.
Shares sold by Pillar Pharmaceuticals III, L.P. ("Pillar III"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar III and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar III. As of the date hereof, Pillar III owns directly 2,355,181 shares of common stock of the Issuer.
Shares sold by Pillar Pharmaceuticals IV, L.P. ("Pillar IV"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar IV and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar IV. As of the date hereof, Pillar IV owns directly 661,547 shares of common stock of the Issuer.
Youssef El Zein is a director and controlling stockholder of Pillar GP and serves as the representative of a Pillar I, Pillar II, Pillar III, Pillar IV and Pillar GP on the Issuer's board of directors. Mr. El Zein disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I, Pillar II, Pillar III, Pillar IV and Besancon and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. El Zein owns directly 586,101 shares of common stock of the Issuer.
Warrants beneficially owned and exercised for shares of common stock by Besancon (the "Besancon Warrants"). Pillar GP disclaims Section 16 beneficial ownership of the Besancon Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, resulting from fees payable to Pillar GP in its capacity as investment advisor to Besancon.
Shares of Common Stock are held directly by Pillar II. Pillar GP disclaims beneficial ownership of the Securities and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest, if any, in the Securities by virtue of its general partner interest in Pillar II.
On December 11, 2014, Pillar II converted 313,341 shares of Series E Convertible Preferred Stock, on a 1-for-20 basis, into 6,266,820 shares of Common Stock.